The AIM-HI Accelerator Fund (AIM-HI) is now accepting applications for the 2026 AIM-HI Venture Competition, including the Women’s Venture Competition and the BRACE (Bridging Research from Academia to Cancer Entrepreneurship) Award.

Designed by and for oncology innovators, AIM-HI offers more than capital. Contestants gain access to a high-caliber global network of scientific leaders, clinicians, experienced entrepreneurs, and investors who understand the unique challenges of building companies in cancer.

The winning companies will receive:

  • Catalytic early-stage investment (pre-seed through Series A)
  • Direct mentorship from leaders in oncology research, clinical development, and biotech commercialization
  • Strategic guidance to refine sciecntific, regulatory, and business pathways
  • Visibility and connections within a mission-driven ecosystem committed to accelerating patient impact

Applications are now open!

Women’s Venture Competition

Open to women-led oncology companies with at least one woman in senior leadership who has an equity stake – could be Founder or a C-level executive. APPLY NOW

BRACE Award Venture Competition

Open to innovative oncology startups that can make an impact on cancers prevalent in underserved populations – led by men and women. APPLY NOW

AIM-HI is purpose-built to help entrepreneurs bridge the critical gap between academic discovery and successful cancer entrepreneurship—without forcing compromise on science or mission. We invite you to apply and join a community that invests not just in companies, but in the leaders of next-generation cancer solutions.
Read the Press Release announcing the 2025 Competition Winners, ResNovas Therapeutics and Chiara Biosciences.